Financing a buy-and-build healthcare platform is an instrument-selection problem, not a fundraising one.
Debt or equity for your scaling hospital platform? The right instrument depends on cash generation and stage. What Burjeel's $500m sukuk signals.
What a board member needs before the next meeting on this.
- It is instrument selection, not fundraising. The right capital depends on how much cash the platform already generates and how far along the build it is.
- Cash-generative platforms should carry debt. Burjeel's US$500m sukuk priced ~3.2x oversubscribed; contracted health cash flows service term debt and keep the upside yours.
- Equity is for when the model is still proving. Growth capital absorbs the volatility of the build without demanding fixed servicing during integration.
- Most platforms are a staged mix. Fund the stable base with debt and the growth edge with equity; match the timing of the capital to the timing of the cash.
You are leading a healthcare platform that is scaling by acquisition. The next three or four targets are identified, the integration playbook is written, and the only open question is how to pay for them. Most owners treat that as a fundraising problem and go looking for the largest available cheque. It is an instrument-selection problem. The right capital for a buy-and-build platform depends on how much cash the platform already generates and how far along the build it is, and choosing the wrong instrument for your stage is how good operators end up over-levered or over-diluted.
A cash-generative platform can and should carry debt, and the GCC market now proves it at scale
On 25 June 2026, Burjeel Holdings, listed on the Abu Dhabi Securities Exchange, priced a US$500 million debut sukuk, its first move into public debt capital markets since listing. The five-year instrument, issued under a newly established US$1.5 billion programme, drew an orderbook that peaked at US$1.6 billion, roughly 3.2 times oversubscribed, and priced at a 7.000% profit rate. Burjeel has said the proceeds support refinancing and its long-term priorities across advanced clinical services, research, medical education, and AI-enabled healthcare. The lesson for a private platform is not that you can issue a sukuk tomorrow. It is that predictable, contracted healthcare cash flows service term debt well, and debt funds expansion without surrendering equity. If your platform throws off stable EBITDA across a mature facility base, debt is the cheaper instrument and it keeps the upside yours.
Equity is what you raise when the platform is still proving the model
Early in a buy-and-build, before the acquired sites are integrated and before the earnings are predictable, loading term debt onto the balance sheet is a way to convert an operating stumble into a covenant breach. Private-equity growth capital is priced for exactly that risk. It absorbs the volatility of the build, brings a partner who has consolidated platforms before, and does not demand fixed servicing while you are still standardising billing, clinical governance, and procurement across newly bought facilities. You pay for that with dilution and with a board seat, and for a platform at this stage that is usually the right trade.
Most platforms are not at one pole or the other, which is where staged and phased structures earn their place
A platform that generates cash from its core sites but wants to acquire into a less proven adjacency can fund the stable base with debt and the growth edge with equity. Acquisition facilities that draw down per deal, vendor consideration deferred and tied to earn-outs, mezzanine layered between senior debt and equity, delayed-draw term loans sized to the pipeline rather than to a single close. Each of these matches the timing of the capital to the timing of the cash, so you are not paying to hold money you have not yet deployed. The structuring question is not debt or equity. It is which instrument funds which part of the plan, and in what sequence.
The exit environment is telling you to build for consolidation, not for a listing
The near-term GCC consensus favours consolidation over IPO as the likely outcome for scaled healthcare platforms. That has a direct consequence for how you finance the build now. If the realistic exit is a sale to a larger strategic or a regional consolidator rather than a public offering, you optimise for a clean, integrated, well-governed platform that a buyer can absorb, and you avoid a capital structure so complex that it frightens an acquirer's diligence team. Finance the build with the exit in mind.
The demand case underneath all of this is not in doubt
Alpen Capital projects GCC current healthcare expenditure rising from about US$109 billion in 2024 to about US$159 billion in 2029, a compound annual growth rate near 7.8%, with Saudi Arabia and the UAE expected to hold a combined share above 82% by the end of the period. The region needs more beds, more capacity, and more consolidated operators to run them. Capital is available for platforms that can show they will capture that growth. The discipline is matching the instrument to your stage so that the cost of capital does not eat the return the growth is meant to deliver.
The sequencing is where most of the value is won or lost
Raise equity too early and you dilute before the platform is worth what it will be worth. Take on debt too early and you cap your own flexibility. The right answer changes as the platform matures, which means the financing plan is a multi-year path, not a single round, and it needs a hand on the balance sheet between rounds.
Four questions before the next round
- Does the platform's cash generation support term debt, or would it convert a stumble into a covenant breach?
- Which part of the plan is stable enough for debt, and which needs equity?
- Are we building for a consolidation exit rather than an IPO, and does our capital structure reflect that?
- Is the financing a multi-year path with a hand on the balance sheet between rounds?
If you are scaling a hospital or medical-center-group platform and weighing sukuk, private equity, or a staged structure, Avior's capital-raise and CFO advisory team will match the instrument to your stage and run the process.